DAFNA Capital Management LLC recently announced the acquisition of new stake in BrainsWay Ltd. (NASDAQ:BWAY). The institutional investor has increased its shareholding in the Healthcare company by 10.00% to 0.22 million shares with purchase of 20000.0 shares. This fresh investment now brings its stake to 1.33% valued currently at $0.54 million. In addition, Taylor Frigon Capital Management raised its holdings by 1622.0 to 0.21 million shares.
With over 0.11 million BrainsWay Ltd. (BWAY) shares trading Monday and a closing price of $2.10 on the day, the dollar volume was approximately $0.22 million. The shares have shown a negative half year performance of -65.35% and its price on 01/23/23 gained nearly 2.94%. Currently, there are 16.54M common shares owned by the public and among those 15.70M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for BWAY have a consensus price objective of $7.63. The analysts have set the share’s price value over the next 12 months at a high of $14.00 and a low of $3.75. The average price target is 73.91% above its recent price level and an upside to the estimated low will see the stock gain 44.0% over that period. But an upside of 85.0% will see the stock hit the forecast high price target while median target price for the stock is $5.25.
The top 3 mutual fund holders in BrainsWay Ltd. are Wasatch Micro Cap Value Fund, Clearwater Select Equity Fund, and Forte. Wasatch Micro Cap Value Fund owns 0.63 million shares of the company’s stock, all valued at over $1.55 million. The company sold 15000.0 shares recently to bring their total holdings to about 3.80% of the shares outstanding. Clearwater Select Equity Fund sold 477.0 shares to see its total holdings shrink to 0.11 million shares valued at over $0.27 million and representing 0.67% of the shares outstanding. Forte bought 34881.0 shares to bring its total holdings to over 34881.0 shares at a value of $86156.0. Forte now owns shares totaling to 0.21% of the shares outstanding.
Shares of BrainsWay Ltd. (NASDAQ: BWAY) opened at $2.20, up $0.16 from a prior closing price of $2.04. However, the script later moved the day high at 2.2000, up 2.94%. The company’s stock has a 5-day price change of -10.26% and -39.13% over the past three months. BWAY shares are trading -14.98% year to date (YTD), with the 12-month market performance down to -72.97% lower. It has a 12-month low price of $1.64 and touched a high of $9.18 over the same period. BWAY has an average intraday trading volume of 130.82K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.19%, -4.94%, and -54.55% respectively.
Institutional ownership of BrainsWay Ltd. (NASDAQ: BWAY) shares accounts for 38.24% of the company’s 16.54M shares outstanding. Mutual fund holders own 34.44%, while other institutional holders and individual stakeholders account for 4.97% and — respectively.
It has a market capitalization of $37.89M. The earnings-per-share (ttm) stands at -$0.43. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.47% over the week and 8.97% over the month.
Analysts forecast that BrainsWay Ltd. (BWAY) will achieve an EPS of -$0.06 for the current quarter, -$0.05 for the next quarter and -$0.16 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.06 while analysts give the company a high EPS estimate of -$0.06. Comparatively, EPS for the current quarter was -$0.22 a year ago.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate BrainsWay Ltd. (BWAY) as a “Strong Buy” at a consensus score of 1.80. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the BWAY, a number of firms have released research notes about the stock. Loop Capital stated their Buy rating for the stock in a research note on March 03, 2022, with the firm’s price target at $15. H.C. Wainwright coverage for the BrainsWay Ltd. (BWAY) stock in a research note released on July 19, 2021 offered a Buy rating with a price target of $17. Northland Capital was of a view on April 20, 2021 that the stock is Outperform, while Raymond James gave the stock Outperform rating on May 13, 2019, issuing a price target of $14. Oppenheimer on their part issued Outperform rating on May 13, 2019.